<DOC>
	<DOCNO>NCT00064116</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know whether combination chemotherapy effective without rituximab treat patient non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study four different combination chemotherapy regimens rituximab see well work compare four different combination chemotherapy regimens alone treating patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Rituximab Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare time treatment failure patient CD20-positive diffuse large B-cell non-Hodgkin 's lymphoma treat CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisone ) -like chemotherapy v without rituximab . - Compare tumor control , progression rate , complete remission rate patient treat regimen . - Compare disease-free overall survival rate patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center , bulky disease ( vs yes ) , International Prognostic Index score ( 0 vs 1 ) , chemotherapy ( CHOP vs CHOEP v PMitCEBO v MACOP-B ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive 1 follow chemotherapy regimen accord participate country : - CHOP : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 oral prednisone prednisolone day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - CHOEP-21 : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 ; etoposide IV day 1-3 ; oral prednisone day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - PMitCEBO : Patients receive mitoxantrone IV , cyclophosphamide IV , etoposide IV day 1 ; vincristine IV bleomycin IV day 8 ; oral prednisolone daily week 1-4 every day week 5 . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . - MACOP-B : Patients receive cyclophosphamide IV doxorubicin IV day 1 , 15 , 29 , 43 , 57 , 71 ; methotrexate IV vincristine IV day 8 , 36 , 64 ; bleomycin IV vincristine IV day 22 , 50 , 78 ; oral intramuscular prednisone day 1-84 . Treatment continue absence disease progression unacceptable toxicity . - Arm II : Patients receive arm I regimens ( accord participate country ) rituximab follow : - CHOP rituximab : Patients receive CHOP arm I rituximab IV day 1 . - CHOEP-21 rituximab : Patients receive CHOEP-21 arm I rituximab IV day 1 . - PMitCEBO rituximab : Patients receive PMitCEBO arm I rituximab IV day 1 course 1 4 ; day 8 course 2 5 ; day 1 1 4 week completion last course PMitCEBO chemotherapy . - MACOP-B rituximab : Patients receive MACOP-B arm I rituximab IV day 1 , 22 , 43 , 64 , 85 , 106 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 820 patient accrue study within approximately 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large Bcell nonHodgkin 's lymphoma accord REAL classification Diagnosed within past 6 week CD20+ disease Ann Arbor stage II , III , IV disease stage I bulky disease International Prognostic Index ( IPI ) score 0 1 Score 0 define following : Stage I II disease ECOG performance status 0 1 Lactic dehydrogenase ( LDH ) great upper limit normal ( ULN ) Score 1 define 1 following : Stage I II disease ; ECOG performance status 0 1 ; LDH great ULN Stage I II disease ; ECOG performance status 2 3 ; LDH great ULN Stage III IV disease ; ECOG performance status 0 1 ; LDH great ULN Previously untreated disease Mediastinal Bcell lymphoma allow No secondary lymphoma prior chemotherapy radiotherapy malignancies No transform lymphoma No primary CNS lymphoma No primary gastrointestinal ( MALT ) lymphoma No posttransplant lymphoproliferative disorder PATIENT CHARACTERISTICS : Age 18 60 Performance status See Disease Characteristics ECOG 03 Life expectancy At least 3 month Hematopoietic Not specify Hepatic Bilirubin great 2.0 mg/dL* Transaminases great 3 time normal* No active chronic hepatitis B C infection NOTE : *Unless related lymphoma Renal Creatinine great 2 time normal* NOTE : *Unless related lymphoma Cardiovascular No myocardial infarction within past 6 month No uncompensated heart failure No dilatative cardiomyopathy No coronary heart disease ST segment depression ECG No severe uncompensated hypertension Pulmonary No chronic lung disease hypoxemia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No known allergic reaction foreign proteins No prior malignancy except basal cell skin cancer carcinoma situ cervix No concurrent disease would preclude study treatment No active infection require systemic antibiotic antiviral medication No severe uncompensated diabetes mellitus No clinical sign cerebral dysfunction No severe psychiatric disease PRIOR CONCURRENT THERAPY : Biologic therapy No prior murine antibody Chemotherapy No concurrent anticancer chemotherapy Endocrine therapy Not specify Radiotherapy No concurrent responseadapted ( slow response unconfirmed complete response ) radiotherapy Surgery Not specify Other No prior lymphomaspecific treatment More 12 week since prior participation another clinical trial No prior participation study No concurrent study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>